Literature DB >> 18587323

Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status.

Alessandro Lugli1, Alexandar Tzankov, Inti Zlobec, Luigi Maria Terracciano.   

Abstract

The differentiation of colorectal cancer from primary tumors at other sites can be challenging. Often a panel of immunohistochemical protein markers is needed to distinguish between these entities. Protein expression differs significantly in colorectal cancer depending on mismatch repair status and is also heterogeneous among mismatch repair-proficient or -deficient tumors. The aim of this study was to systematically analyze the diagnostic and prognostic role of the commonly used multi-marker phenotype CK20/CK7/CDX2 on a large series of colorectal cancers stratified by mismatch repair status. The immunohistochemical analysis of CK20, CK7 and CDX2 was performed on 1197 mismatch repair-proficient and 223 mismatch repair-deficient colorectal cancers using a tissue microarray. Multi-marker combinations of CK20/CK7/CDX2 were explored. Univariate and multivariable analysis of the markers was evaluated for their association with several clinico-pathological end points namely T stage, N stage, tumor grade, vascular invasion, intratumoral lymphocytes and survival. Multi-marker phenotypes with CK20 and CDX2 negativity were more frequently found in mismatch repair-deficient than in mismatch repair-proficient colorectal cancer (19.3 vs 7.5% and 21.6 vs 6.7%, respectively; P<0.001). In both colorectal cancer subsets loss of CK20 was associated with higher tumor grade (P<0.001) and with presence of intratumoral lymphocytes (P<0.001 and P=0.02, respectively). In the proficient mismatch repair subset CK20 overexpression was an independent adverse prognostic factor (P=0.041) and CDX2 underexpression was linked to tumor progression. Loss of CDX2 and CK20 is more frequently encountered in mismatch repair-deficient colorectal cancer, which should be taken into consideration to differentiate between primary and metastatic colorectal cancer in daily practice. Although associated with lower tumor grade, CK20 overexpression is an independent adverse prognostic factor in mismatch repair-proficient colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587323     DOI: 10.1038/modpathol.2008.117

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  44 in total

1.  CDX2 as a marker for intestinal differentiation: Its utility and limitations.

Authors:  Reda S Saad; Zeina Ghorab; Mahmoud A Khalifa; Mei Xu
Journal:  World J Gastrointest Surg       Date:  2011-11-27

2.  Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.

Authors:  Jeong Mo Bae; Tae Hun Lee; Nam-Yun Cho; Tae-You Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 3.  Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.

Authors:  Jung Ho Kim; Gyeong Hoon Kang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Logarithmic expansion of LGR5+ cells in human colorectal cancer.

Authors:  Maria Laura Martin; Zhaoshi Zeng; Mohammad Adileh; Adrian Jacobo; Christy Li; Efsevia Vakiani; Guoqiang Hua; Lixing Zhang; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick; Philip B Paty
Journal:  Cell Signal       Date:  2017-09-25       Impact factor: 4.315

5.  CDX2 as a Prognostic Biomarker in Colon Cancer.

Authors:  Marta Schirripa; Fotios Loupakis; Heinz-Josef Lenz
Journal:  N Engl J Med       Date:  2016-06-02       Impact factor: 91.245

6.  Defective DNA Mismatch Repair Influences Expression of Endometrial Carcinoma Biomarkers.

Authors:  Ekene I Okoye; Amanda S Bruegl; Bryan Fellman; Rajyalakshmi Luthra; Russell R Broaddus
Journal:  Int J Gynecol Pathol       Date:  2016-01       Impact factor: 2.762

7.  Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report.

Authors:  Tessa P Sandberg; Iris Sweere; Gabi W van Pelt; Hein Putter; Louis Vermeulen; Peter J Kuppen; Rob A E M Tollenaar; Wilma E Mesker
Journal:  Cell Oncol (Dordr)       Date:  2019-03-08       Impact factor: 6.730

8.  Molecular Modifiers of Hormone Receptor Action: Decreased Androgen Receptor Expression in Mismatch Repair Deficient Endometrial Endometrioid Adenocarcinoma.

Authors:  Qiong Gan; Suzanne Crumley; Russell R Broaddus
Journal:  Int J Gynecol Pathol       Date:  2019-01       Impact factor: 2.762

9.  Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.

Authors:  Kjersti Elvestad Hestetun; Kristine Aasebø; Nina Benedikte Rosenlund; Yvonne Müller; Olav Dahl; Mette Pernille Myklebust
Journal:  Mod Pathol       Date:  2020-07-31       Impact factor: 7.842

10.  Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.

Authors:  Frank Serge Lehmann; Francesca Trapani; Ida Fueglistaler; Luigi Maria Terracciano; Markus von Flüe; Gieri Cathomas; Andreas Zettl; Pascal Benkert; Daniel Oertli; Christoph Beglinger
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.